Author

P. J. Cimino

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Organism:mouse· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

E. C. Holland· 3 shared F. Szulzewsky· 3 shared S. Arora· 3 shared F. Sahm· 2 shared J. Shendure· 2 shared N. Nuechterlein· 2 shared P. Sievers· 2 shared A. Arakaki· 1 shared

Activity by Year

2019-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. C. Holland

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Meningioma transcriptomic landscape demonstrates novel subtypes with regional associated biology and patient outcome.

H. N. Thirimanne, D. A. Bonnin, N. Nuechterlein, S. Arora, M. Jensen, C. A. Parada, C. Qiu, F. Szulzewsky, C. W. English, W. C. Chen, P. Sievers, F. Nassiri, J. Z. Wang, T. J. Klisch, K. D. Aldape, , E. C. Holland

This study combines bulk RNA-Seq datasets to create a transcriptomic landscape of meningiomas, identifies subtypes with distinct biology and prognosis, and provides an interactive tool for outcome prediction.

bioRxiv · Feb 23, 2024Cancer Biology

MAIT cells have a negative impact on glioblastoma

S. keretsu, T. Hana, A. Lee, N. Kedei, N. Malik, H. Kim, J. Spurgeon, G. Khayrullina, B. Ruf, A. Hara, M. Coombs, M. Watowich, M. Watanabe, A. Hari, M. K. B. Ford, , M. Terabe

The paper identifies MAIT cells as immunosuppressive in glioblastoma, correlating their presence with poor patient survival and immune suppressive gene upregulation.

bioRxiv · Jul 17, 2022 · PreprintImmunology

Both YAP1-MAML2 and constitutively active YAP1 drive the formation of tumors that resemble NF2-mutant meningiomas in mice

F. Szulzewsky, S. Arora, A. Arakaki, P. Sievers, D. A. A. Bonnin, P. J. Paddison, F. Sahm, P. J. Cimino, T. Gujral, E. C. Holland

This study shows that YAP1-MAML2 and active YAP1 drive tumors resembling NF2-mutant meningiomas in mice through TEAD-dependent YAP activity.

bioRxiv · May 2, 2022 · PreprintCancer Biology

Oncogenic role of a developmentally regulated NTRK2 splice variant

S. S. Pattwell, S. Arora, N. Nuechterlein, M. Zager, K. R. Loeb, P. J. Cimino, N. C. Holland, N. Reche-Ley, H. Bolouri, D. A. A. Bonin, F. Szulzewsky, V. V. Phadnis, T. Ozawa, M. J. Wagner, M. C. Haffner, , E. C. Holland

The paper identifies TrkB.T1, an embryonic NTRK2 splice variant, as an oncogenic driver in multiple tumor types across species, with distinct interactors in developmental and oncogenic pathways.

bioRxiv · Jan 7, 2022 · PreprintCancer Biology

Beyond Conventional Models: Recreating the Initiation, Evolution, and Genome of GBM

A. Bohm, J. DePetro, C. Binding, A. Gerber, N. Chahley, M. Ware, K. Thomas, S. Bukhari, C. Chen, E. Chahley, C. Grisdale, N. D. Berger, S. Lawn, Y. Yu, R. Wong, , G. Cairncross

This study develops a mouse model of glioblastoma (GBM) that replicates its genomic landscape and early stages, enabling research into prevention and treatment strategies.

bioRxiv · Nov 9, 2019 · PreprintCancer Biology